Study Information | Coverage | Pre-Implementation and Expansion | Post-Implementation and Expansion | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Investigator | Location | Study Design | Syringes per PWID/Year1 | Year | (n) | HIV prev. | HCV prev. | Estimated HIVinc.2 | HCV inc. | Year | (n) | HIV prev.3 | HCV prev.3 | Estimated HIVinc.2 | HCV inc. |
Gray 1998 [25] | Chiang Rai, Thailand | Time Series Cross Sectional | 150-160 | 1993 | 46 | 33% | Â | Â | Â | 1996 | 132 | 18% (15%) | Â | Â | Â |
Caiaffa 2003 [26] | Porto Alegre, Brazil | Pre-Post Study Comparison | 6-20 | 1998 | 137 | 49% | Â | Â | Â | 2001 | 255 | 64.3% (+16%) | Â | Â | Â |
Wu 2007 [27] | Dagou, China | Pre-Post Study Comparison | 290-300 | 2002 | 235 | 40% | 99% | Â | Â | 2003 | 226 | 34% (6%) | 89% (10%) | Â | Â |
Luzhai, China | Pre-Post Study Comparison | 140-150 | 2002 | 194 | 56% | 89% | Â | Â | 2003 | 219 | 53% (3%) | 85% (4%) | Â | Â | |
Azim 2008 [28] | Dhaka, Bangladesh | Time Series Cross Sectional | 285-344 | 1990 | 418 | 2% | 67% | Â | Â | 2006 | 1092 | 7% (+5%) | 57% (10%) | Â | Â |
Azim 2009 [29] | Dhaka, Bangladesh | Time Series Cross Sectional | 285-344 | 1999 | 418 | Â | Â | Â | 1.2/100 PY | 2007 | 1045 | Â | Â | Â | 1.3/100 PY |
Uuskula 2011 [30] | Tallinn, Estonia | Time Series Cross Sectional | 23-78 | 2005 | 350 | 54% | Â | 20.9/100 PY | Â | 2009 | 327 | 50% (4%) | Â | 9/100 PY | Â |
Hammett 2012 [31] | Ning Ming, China | Time Series Cross Sectional | 20-30 | 2002 | 290 | 17% | Â | 12/100 PY | Â | 2008 | 187 | 11% (6%) | Â | 11/100 PY | Â |
 | Lang Son, Vietnam | Time Series Cross Sectional | 20-30 | 2002 | 342 | 46% |  | 22/100 PY |  | 2009 | 185 | 23% (23%) |  | 3/100 PY |  |